Physician profile
Luke J Halbur
NPI 1295709996
$10,201.39
in general payments reported to CMS, 2019-2025
55 companies · $1,484 in 2025
The $1,484 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,433 · 2020: $578 · 2021: $1,335 · 2022: $1,907 · 2023: $1,406 · 2024: $2,059 · 2025: $1,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,808 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,807.71 |
| Education | $140.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $842.03 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| Pfizer INC. | $829.88 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $702.05 | 2019-2025 | |
| Janssen Biotech, INC. | $691.48 | 2019-2025 | Erleada, Balversa, Akeega |
| Merck Sharp & Dohme LLC | $665.03 | 2019-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $518.66 | 2019-2025 | Opdivo |
| Celgene Corporation | $498.09 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Genentech USA, INC. | $434.30 | 2019-2025 | Alecensa, Tecentriq, Lunsumio |
| Abbvie INC. | $431.73 | 2019-2025 | |
| Daiichi Sankyo INC. | $342.47 | 2020-2025 | Enhertu, Vanflyta |
| Amgen INC. | $303.45 | 2019-2023 | Lumakras |
| Gilead Sciences, INC. | $262.05 | 2019-2025 | Trodelvy |
| Astellas Pharma US INC | $258.36 | 2020-2025 | Xtandi, Vyloy, Xospata |
| Genzyme Corporation | $237.09 | 2019-2025 | |
| Exelixis INC. | $208.68 | 2019 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Halbur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.